Research on new and better ways to treat cancer. Covers radiotherapy, targeted microdroplets, nerve-injury protection, drug combinations, and tumor models.
Researchers at UT MD Anderson Cancer Center have made significant breakthroughs in cancer treatment, including a promising new therapy for patients with specific EGFR-mutated lung cancer. Additionally, a study published in Science has provided new insights into the cell environment surrounding early breast cancers, shedding light on wh...
Scientists identify chimeric RNA molecules as essential in cellular health and disease, finding they play a wide variety of critical roles in vital cellular processes. Faulty chimeric RNA are often malfunctioning in breast cancer tumors, prompting new cancer treatments targeting specific chimeras.
A new study published in JNCCN found that comprehensive biomarker testing before treatment for advanced lung cancer was associated with patients living longer. Broad-based genomic sequencing helped identify a wider range of tumor biomarkers, guiding targeted treatment and improving survival outcomes.
Researchers developed a combination therapy approach using TargetScore algorithm to target PARP and SHP2 proteins, overcoming treatment resistance in breast cancer models. This approach showed durable responses and improved survival in multiple preclinical models.
A new treatment approach combining immunotherapy with targeted cancer drug enfortumab vedotin improves survival in patients with muscle-invasive bladder cancer. The treatment reduces the risk of death by 42% and cancer recurrence or progression by 49% in patients unable to receive standard chemotherapy.
The UVA Biotech Innovation Fund will support the SPARK Innovative Medicines program, helping to accelerate promising discoveries into new treatments and cures. The fund will provide long-term support for researchers to overcome the critical gap between discovery and clinical application.
Alliance Clinical Trials is advancing early detection, improving treatments, and enhancing survivorship for lung cancer patients. The organization is conducting seven active clinical trials focused on prevention, early detection, treatment, and survivorship.
Simple automated text reminders and personalized telephone support increased bowel cancer screening uptake among non-responders in London, with 6.5% of initial non-responders completing their test kits. The interventions detected an additional 50 extra cancers annually, bridging the eight-percentage-point gap with the national average.
The National Comprehensive Cancer Network (NCCN) has signed an agreement with the Viet Nam National Cancer Hospital to expand cancer care resources in Vietnam. The collaboration aims to improve cancer care through the adaptation and use of evidence-based clinical practice guidelines.
A new study from UCLA found that most breast cancer recurrences after double mastectomy were detected through symptoms or clinical concerns, rather than routine screening. The study suggests that routine imaging may offer limited benefit for women with no symptoms after surgery.
A new molecular map of breast cancer has identified novel forms of the disease and provides a foundation for selecting personalized treatments. The atlas groups breast cancers into interconnected clusters sharing common molecular features, treatment responses, and clinical outcomes.
Researchers have discovered a vulnerability in the WNT pathway, a common driver of cancer, and are developing a drug compound to exploit it. The strategy targets a selective enzyme inhibitor that reduces WNT signaling in cancer cells with minimal effect on healthy cells.
Researchers found that high blood sugar can reprogram immune cells to better control tumor growth, increasing cancer-fighting abilities. This understanding could lead to new cancer immunotherapies that mimic these changes.
A newly discovered pathway helps cancer cells selectively produce proteins that drive tumor growth, including KRAS. Targeting the METTL13 enzyme may improve responses to targeted therapies and help overcome treatment resistance.
A family of mutations in the BAF complex is found in 20% of human cancers, driving malignancy by altering gene accessibility to CTCF. CTCF's role in reshaping DNA is confirmed in multiple cancer types, suggesting potential therapeutic targets for BAF-mutant cancers.
A new study led by UC Davis researchers finds that narrower surgical margins than previously thought can achieve cancer control in pediatric patients with non-rhabdomyosarcoma soft tissue sarcomas. The study, which evaluated 266 patients, found that close surgical margins as little as a millimeter can preserve precious healthy tissue a...
The new NCCN Guidelines for Patients: Caregiving for People with Cancer offer concrete tips for handling difficult situations and provide concrete support for caregivers. The guide includes a chapter dedicated to the caregiver's own wellbeing, emphasizing the importance of self-care and providing trusted, easy-to-find information.
The updated guideline recommends moderate hypofractionation over conventional fractionation for patients across all prostate cancer risk groups who choose EBRT, supported by high-quality randomized data showing comparable outcomes, side effects and quality of life. Ultrahypofractionation is also strongly recommended as a standard optio...
A recent analysis reveals a decline in low-risk prostate cancer diagnoses and increased use of active surveillance, indicating a shift away from overtreatment. This change is attributed to growing concerns about overdiagnosis and overtreatment, leading to reduced treatment among patients with low-risk cancers.
A new drug called sacituzumab tirumotecan has been shown to significantly reduce the recurrence and death from endometrial cancer. In a phase 3 trial, women treated with sac-TMT had a 41% lower risk of their cancer progressing and a 32% lower risk of death compared to those treated with standard chemotherapy.
MIT researchers have designed an implantable drug-delivery device that uses ultrasound to enhance the distribution of drug molecules in the brain. The device, called LUCID, can release drugs over an extended period and bypass the blood-brain barrier, offering a potential way to prevent the recurrence of aggressive brain tumors.
Targeting fat cells with sphingosine kinase 2 inhibitors could be a new strategy to combat obesity and lower the risk of its comorbidities like cancer. The researchers found a significant reduction in body weight, improved glucose tolerance, and reduced lipid accumulation in the liver.
A new analysis of a phase 3 clinical trial found that daraxonrasib improved survival compared with standard chemotherapy across multiple groups of patients with advanced pancreatic cancer. The treatment consistently provided a benefit regardless of tumor RAS mutation status or previous treatment history.
Cancers can evade chemotherapy by entering a 'zombie-like state' called premature senescence, which tricks the immune system into helping malignant cells. This phenomenon allows tumours to acquire extra oxygen and nutrients, making them more resistant to chemotherapy.
A groundbreaking immunotherapy treatment for rectal cancer has received FDA approval, offering patients with locally advanced rectal cancer the possibility of eliminating their cancer without chemotherapy, radiation, or surgery. The treatment, developed through pioneering research at Memorial Sloan Kettering Cancer Center, has shown a ...
Researchers at RIKEN have developed a synthetic compound that uses excess carbon monoxide produced by cancer cells to trigger the production of anti-cancer drugs within the cells themselves. The compound selectively targets tumors and avoids harming healthy cells, offering a promising new approach to cancer treatment.
A new trial shows that a shorter three-week radiation course is as safe and effective as the standard five-week treatment for women undergoing breast reconstruction. The RT CHARM trial found no increase in complications or effects on reconstruction efforts.
A new AI platform, MAESTRO, has been developed to identify promising drug combinations for overcoming treatment resistance in prostate cancer. The platform uses large language models to analyze scientific knowledge and ranks the most promising candidates, providing a clear biological rationale for experimental testing.
A new study found that oxaloacetate, a molecule that helps cells produce energy, may improve cognitive function and reduce fatigue in breast cancer survivors with 'chemo brain' or brain fog. The study showed significant improvements in memory, concentration, and physical functioning after 8 weeks of treatment.
HistoIndex and A*STAR collaborate on preclinical evaluation of therapeutic candidates for fibrotic diseases, utilizing AI-powered tissue analysis and imaging technology. The partnership aims to improve the evaluation of fibrosis and treatment response, supporting informed decision-making in therapeutic development.
A new study found that adding 3D goggles to deep-inspiratory breath-hold radiotherapy did not significantly reduce treatment time. However, setup time was longer when goggles were used, and treatment efficiency improved with repeated sessions.
UT MD Anderson Cancer Center has made significant advancements in cancer care, including the development of a covalent Werner helicase inhibitor, which showed promising antitumor efficacy in a Phase 1 trial. Additionally, a multicenter clinical trial found that tile-based radiation therapy improved tumor control and lowered the risk of...
Scientists discover aberrant antibodies in children with cancer, targeting DNA repair proteins, which may hinder normal repair and lead to cancer. The findings suggest a potential mechanism for pediatric cancer development and may lead to early screening and prevention.
Researchers at TU Wien and MedAustron have developed a new approach combining carbon and helium ions to monitor tumor anatomy during treatment while destroying cancer cells. This method allows for reduced safety margins and spared healthy tissue, particularly near sensitive organs.
Two UCLA-led studies reveal features of effective immune responses in glioblastoma and introduce a preclinical model that more closely mirrors the human disease. Long-term survivors showed evidence of a stronger immune response within their tumors, offering important clues for developing treatments.
A new UCLA study suggests that adding a targeted radioactive drug to stereotactic body radiation therapy may help delay the spread of recurrent prostate cancer. The treatment showed a 62% lower risk of progression or needing additional hormone therapy, and improved control of disease on conventional imaging.
New research suggests that mitochondrial DNA (mtDNA) copy number affects cancer severity and therapy response. High mtDNA copy number is linked to the expression of genes that support tumor growth and survival. The study's findings could pave the way for new cancer management strategies.
Tampere University Hospital is introducing a novel radiotherapy to treat rectal cancer, targeting the tumour surface with high doses of radiation. This treatment aims to destroy the tumour, potentially avoiding major surgery and a stoma, and is being investigated in the NORPPA-2 study.
A significant proportion of patients with HER2-positive, ER-negative breast cancer can achieve a pathologic complete response after 12 weeks of THP chemotherapy. The trial identified ER-negative or low ER-expressing tumors, low or no progesterone receptor expression, HER2 IHC 3+ tumors, and weekly paclitaxel treatment as key predictors...
Researchers identify key role of spatial niche in early gastric cancer initiation and progression, highlighting inflammation-associated spatial niche as fundamental regulatory unit. Targeting inflammation-associated spatial niches may enable earlier and more precise therapeutic strategies.
Researchers found that the cancer drug zavondemstat and a closely related compound QC6352 do not primarily target KDM4, but instead work by blocking DHODH, an enzyme cancer cells rely on to produce molecules needed for rapid growth. This discovery highlights a broader challenge in cancer drug development, emphasizing the need for great...
Dr. Michael Taylor, a pediatric neurosurgeon and researcher, has received a Texans Conquer Cancer Award from CPRIT for his work on childhood brain tumors. His research aims to identify effective treatments that improve survival while reducing long-term effects.
Dr. Dennis Slamon, a pioneer in breast cancer research, has been awarded the 2026 Albany Prize for his groundbreaking work on targeted cancer treatments. His discovery of the HER2 protein and the development of Herceptin have transformed the understanding and treatment of breast cancer, saving millions of lives worldwide.
The review proposes co-designing oncolytic viruses and CAR cells to overcome solid tumor barriers, enabling a self-amplifying therapeutic system. Oncolytic viruses can be engineered to deliver payloads, expanding target recognition and maintaining CAR cell function.
KRAS mutations define a distinct molecular subset of gastric adenocarcinoma with poor response to immunotherapy. KRAS inhibition combined with CTLA-4 blockade overcomes immunotherapy resistance by attenuating TGF-beta activity and impairing regulatory T cell function, sensitizing tumors to CTLA-4 immunotherapy.
Researchers discovered gallic acid suppresses tumor progression by targeting the NF-κB/KLF7/L1CAM axis in prostate cancer. The study demonstrated that gallic acid significantly impaired aggressive behaviors of PC-3 and LNCaP cells without toxicity to normal cells.
A new surgical technique has been developed to restore the clitoris after treatment for vulvar cancer, with 90% of patients able to achieve clitoral orgasm again. The procedure, which adds only 15 minutes to the operation, preserves clitoral sensation and improves sexual function and quality of life.
The new NCCN Guidelines for Pediatric Bone Sarcoma focus on Ewing sarcoma and other undifferentiated round cell sarcomas, aiming to provide clear medical roadmaps for patients and their families. With a 5-year survival rate of 81% for early-stage diagnosis, these guidelines can help ensure teenagers receive optimal treatment and support.
Researchers have developed a practical strategy to recover biosynthetic information from fragmented metagenomic data, identifying promising natural-product candidates with potential antibacterial or anticancer activity. The study prioritizes candidates using known biosynthetic gene clusters as guides, enabling the reconstruction of can...
A multidisciplinary approach is crucial for treating recurrent prostate cancer, combining advanced imaging, radiation, and systemic therapies to address microscopic disease. The case report follows Larry Hardesty, who underwent several clinical trials, including PSMA-targeted radioligand therapy, leading to undetectable PSA levels and ...
Researchers developed a mathematical model to understand how the tumor microenvironment affects cancer therapy. The model suggests strategies to
The UVA Weber Symposium will discuss the latest research and advancements in metastasis, a complex area of cancer research and care. The event will bring together top scientists and physicians to present findings on cancer metastasis, genetics, and treatment considerations.
A phase Ib/II trial evaluated the triple combination of famitinib, dalpiciclib, and fulvestrant in HR+/HER2− breast cancer, meeting initial efficacy targets with a confirmed objective response rate of 51.9%. However, the regimen showed no superiority over standard first-line treatments and was terminated early due to safety concerns.
A randomized trial found that five-treatment stereotactic body radiation therapy (SBRT) provided excellent long-term cancer control and better urinary continence and sexual function compared to surgery. SBRT offered clear advantages for urinary continence and sexual function, with 91% of patients remaining free from biochemical or clin...
Patients with small cell lung cancer and brain metastases lived 17.4 months with radiosurgery, compared to 8.6 months with whole brain treatment. Radiosurgery was associated with a 40% lower risk of death. The study challenges the long-standing reliance on whole brain treatment for SCLC brain metastases.
A randomized phase 2 trial found that five treatments of stereotactic body radiation therapy (SBRT) better preserved physical function and reduced fatigue compared to 28 treatments of conventional radiation therapy with chemotherapy. Rates of cancer remaining in lymph nodes did not differ significantly between the groups.
A phase 3 trial found that delivering focused radiation therapy over three to five sessions after surgery for a large brain metastasis reduced cancer recurrence and improved survival. Patients who received multi-session treatment lived nine months longer than those treated in a single session without significantly increasing side effects.
Zhen Xu, U-M Engineering professor, wins Golden Goose Award for development of histotripsy, a noninvasive cancer treatment. The technology has been used to treat over 5,000 patients worldwide and has the potential to treat various diseases, including brain diseases and cardiovascular diseases.
Researchers found implanting collagen tiles during brain surgery to deliver targeted radiation therapy improves tumor control, lowers recurrence risk, and increases overall survival. Patients treated with tile-based radiation therapy had a 1.3% rate of recurrence at the surgical site compared to 15.4% in the control group.
A multi-institutional trial found that ultra-low-dose radiation therapy relieved painful bone lesions from multiple myeloma for most patients, with 81% achieving pain control without additional radiation. Treatment side effects were limited to low-grade fatigue.